Strata Oncology, Inc.

Strata Oncology, Inc. specializes in precision oncology, focusing on developing predictive biomarkers that inform treatment responses to antibody-drug conjugates and immunotherapies, enhancing decision-making in cancer care. Strata Oncology, Inc. , founded in 2015, is based in Ann Arbor, US.

The company develops predictive biomarker solutions to evaluate cancer treatment responses. It has raised funding through three rounds, with the latest being a Series C round in July 2021, where they secured USD 90. 00 mn led by Wellington Management. Founders Dan Rhodes and Scott Tomlins established the company with a vision for advancing personalized cancer treatment solutions.

Strata has not undergone notable pivots or changes in operations since its inception. Strata Oncology offers innovative biomarker solutions aimed at precision oncology, including the Antibody Drug Conjugate Treatment Response Score (ADC TRS) and the Immunotherapy Response Score. These products assist clinicians by providing insights into treatment options based on tumor biology, utilizing algorithms that assess tumor mutation burden and protein expression in the tumor microenvironment. Their client base encompasses biopharmaceutical companies and healthcare providers across North America, Europe, and Asia, enhancing treatment personalization in oncology.

Strata Oncology generates revenue through partnerships with biopharmaceutical companies and healthcare providers, leveraging service agreements that often include licensing fees for their diagnostic tools. Clients typically pay for access to Strata's proprietary scores, integral to treatment planning and patient management. This revenue model fosters long-term collaborations that can lead to further service offerings and product development initiatives. With the USD 90.

00 mn raised in the Series C funding round in July 2021, Strata Oncology intends to expedite the development of its personalized minimal residual disease (MRD) assay aimed at early-stage cancers and expand its pipeline of novel RNA-based treatment selection tests for solid tumors. The company is targeting wider market penetration and plans to enhance its offerings in North America, Europe, and Asia, thereby broadening its global reach, which aligns with its strategic objectives for future growth.